[{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"ROS receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"ROS receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"||Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"||Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"||Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for TLD-1433
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
